Related Experiment Videos
Hematologic malignancies: new developments and future treatments
1Clinical Investigations Branch, National Cancer Institute, Bethesda, MD, USA.
Abstract:
An increasing number of unique active new chemotherapeutic and biologic agents are currently available for clinical research studies. Nucleoside analogs in development for non-Hodgkin's lymphoma (NHL) include clofarabine, troxacitabine, and bendamustine, a hybrid of an alkylating nitrogen mustard group and a purine-like benzimidazole, with demonstrated activity in NHL. Drugs directed at the cell cycle include flavopiridol and UCN-01. The proteasome plays a pivotal role in cellular protein regulation and activation of NFkappaB, which maintains cell viability through the transcription of inhibitors of apoptosis. PS-341 is a specific, selective inhibitor of the 26S proteasome which induces apoptosis and has activity in cell types characterized by overexpression of Bcl-2. Response rates of 50%, including complete remissions, have been reported using this agent in patients with refractory multiple myeloma. Studies are ongoing in NHL and chronic lymphocytic leukemia. G3139, an antisense oligonucleotide, has shown promise in early studies. Rituximab has revolutionized the treatment of NHL. However, other active antibodies are now available, including alemtuzumab, epratuzumab, and Hu1D10. The radioimmunoconjugates (90)Y-ibritumomab tiuxetan and (131)I-tositumomab may also play an important role in the management of NHL. Future therapeutic strategies should involve rational combinations of new chemotherapy drugs, biologic agents, and antisense compounds to increase the cure rate in patients with lymphoma.
Insights
New chemotherapeutic and biologic agents show promise for treating non-Hodgkin's lymphoma (NHL). Research explores nucleoside analogs, cell cycle drugs, proteasome inhibitors like PS-341, and antibodies such as rituximab for improved lymphoma treatment outcomes.
Area of Science:
- Oncology
- Pharmacology
- Hematology
Background:
- Numerous novel chemotherapeutic and biologic agents are emerging for clinical research.
- Non-Hodgkin's lymphoma (NHL) treatment landscape is evolving with new drug classes.
- Understanding cellular mechanisms like proteasome function is key to developing targeted therapies.
Purpose of the Study:
- To review emerging chemotherapeutic and biologic agents for non-Hodgkin's lymphoma (NHL).
- To highlight novel drug classes including nucleoside analogs, cell cycle inhibitors, proteasome inhibitors, and monoclonal antibodies.
- To discuss the potential of these agents and future combination strategies in lymphoma management.
Main Methods:
- Review of current clinical research on novel agents for NHL.
- Categorization of drugs based on their mechanism of action (e.g., nucleoside analogs, proteasome inhibitors, antibodies).
- Summary of reported activity and ongoing studies for key agents.
Main Results:
- Bendamustine, a hybrid molecule, shows demonstrated activity in NHL.
- Proteasome inhibitor PS-341 induces apoptosis and shows efficacy in refractory multiple myeloma, with ongoing NHL studies.
- Antibodies like rituximab, alemtuzumab, and radioimmunoconjugates are significant in NHL management.
Conclusions:
- A variety of novel agents, including nucleoside analogs, cell cycle drugs, proteasome inhibitors, and antibodies, offer new therapeutic options for NHL.
- Agents like PS-341 and radioimmunoconjugates demonstrate significant clinical activity.
- Future strategies emphasize rational combinations of chemotherapy, biologics, and antisense compounds to enhance cure rates in lymphoma patients.